Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges.

Autor:	Gong S; Texas Biomedical Research Institute, San Antonio, TX, United States.; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States., Lakhashe SK; Texas Biomedical Research Institute, San Antonio, TX, United States., Hariraju D; Texas Biomedical Research Institute, San Antonio, TX, United States.; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States., Scinto H; Texas Biomedical Research Institute, San Antonio, TX, United States.; Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, TX, United States., Lanzavecchia A; Institute for Research in Biomedicine, Bellinzona, Switzerland.; Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Cameroni E; Institute for Research in Biomedicine, Bellinzona, Switzerland.; Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Corti D; Institute for Research in Biomedicine, Bellinzona, Switzerland.; Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Ratcliffe SJ; University of Pennsylvania, Philadelphia, PA, United States., Rogers KA; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States.; Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States., Xiao P; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States., Fontenot J; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States., Villinger F; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States.; Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States., Ruprecht RM; Texas Biomedical Research Institute, San Antonio, TX, United States.; New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA, United States.; Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, TX, United States.; Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Aug 03; Vol. 12, pp. 705592. Date of Electronic Publication: 2021 Aug 03 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.705592
Abstrakt:	Understanding the interplay between systemic and mucosal anti-HIV antibodies can provide important insights to develop new prevention strategies. We used passive immunization via systemic and/or mucosal routes to establish cause-and-effect between well-characterized monoclonal antibodies and protection against intrarectal (i.r.) SHIV challenge. In a pilot study, for which we re-used animals previously exposed to SHIV but completely protected from viremia by different classes of anti-HIV neutralizing monoclonal antibodies (mAbs), we made a surprise finding: low-dose intravenous (i.v.) HGN194-IgG1, a human neutralizing mAb against the conserved V3-loop crown, was ineffective when given alone but protected 100% of animals when combined with i.r. applied HGN194-dIgA2 that by itself had only protected 17% of the animals. Here we sought to confirm the unexpected synergy between systemically administered IgG1 and mucosally applied dIgA HGN194 forms using six groups of naïve macaques (n=6/group). Animals received i.v. HGN194-IgG1 alone or combined with i.r.-administered dIgA forms; controls remained untreated. HGN194-IgG1 i.v. doses were given 24 hours before - and all i.r. dIgA doses 30 min before - i.r. exposure to a single high-dose of SHIV-1157ipEL-p. All controls became viremic. Among passively immunized animals, the combination of IgG1+dIgA2 again protected 100% of the animals. In contrast, single-agent i.v. IgG1 protected only one of six animals (17%) - consistent with our pilot data. IgG1 combined with dIgA1 or dIgA1+dIgA2 protected 83% (5/6) of the animals. The dIgA1+dIgA2 combination without the systemically administered dose of IgG1 protected 67% (4/6) of the macaques. We conclude that combining suboptimal antibody defenses at systemic and mucosal levels can yield synergy and completely prevent virus acquisition. Competing Interests: AL, DC and EC are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Gong, Lakhashe, Hariraju, Scinto, Lanzavecchia, Cameroni, Corti, Ratcliffe, Rogers, Xiao, Fontenot, Villinger and Ruprecht.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu